VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Highly active RMS as defined by                    │ Highly active RMS as defined by                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ One relapse in the previous year and at least 1 T1 │ One relapse in the previous year and at least 1 T1 │     100 │
│ Gadolinium (Gd)+ lesion or 9 or more T2 lesions,   │ Gadolinium (Gd)+ lesion or 9 or more T2 lesions,   │         │
│ while on therapy with other disease modifying      │ while on therapy with other disease modifying      │         │
│ drugs (DMDs)                                       │ drugs (DMDs)                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Two or more relapses in the previous year, whether │ Two or more relapses in the previous year, whether │     100 │
│ on DMD treatment or not                            │ on DMD treatment or not                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other protocol defined inclusion criteria could    │ Other protocol defined inclusion criteria could    │     100 │
│ apply                                              │ apply                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous exposure to drugs such as fingolimod,     │ Previous exposure to drugs such as fingolimod,     │     100 │
│ natalizumab, alemtuzumab, mitoxantrone and         │ natalizumab, alemtuzumab, mitoxantrone and         │         │
│ ocrelizumab                                        │ ocrelizumab                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive hepatitis C or hepatitis B surface        │ Positive hepatitis C or hepatitis B surface        │     100 │
│ antigen test and/or hepatits B core antibody test  │ antigen test and/or hepatits B core antibody test  │         │
│ for immunoglobulin G (IgG) and/or immunoglobulin M │ for immunoglobulin G (IgG) and/or immunoglobulin M │         │
│ (IgM)                                              │ (IgM)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current or previous history of immune deficiency   │ Current or previous history of immune deficiency   │     100 │
│ disorders including a positive human               │ disorders including a positive human               │         │
│ immunodeficiency virus (HIV) result                │ immunodeficiency virus (HIV) result                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently receiving immunosuppressive or           │ Currently receiving immunosuppressive or           │     100 │
│ myelosuppressive therapy with, for example,        │ myelosuppressive therapy with, for example,        │         │
│ monoclonal antibodies, methotrexate,               │ monoclonal antibodies, methotrexate,               │         │
│ cyclophosphamide, cyclosporine or azathioprine, or │ cyclophosphamide, cyclosporine or azathioprine, or │         │
│ chronic use of corticosteroids                     │ chronic use of corticosteroids                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of tuberculosis , presence of active       │ History of tuberculosis , presence of active       │     100 │
│ tuberculosis, or latent tuberculosis               │ tuberculosis, or latent tuberculosis               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence or suspect of Progressive Multifocal      │ Evidence or suspect of Progressive Multifocal      │     100 │
│ Leukoencephalopathy (PML) in Magnetic Resonance    │ Leukoencephalopathy (PML) in Magnetic Resonance    │         │
│ Imaging (MRI)                                      │ Imaging (MRI)                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active malignancy or history of malignancy         │ Active malignancy or history of malignancy         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other protocol defined exclusion criteria could    │ Other protocol defined exclusion criteria could    │     100 │
│ apply                                              │ apply                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Expanded Disability Status Scale (EDSS) score less │ Expanded Disability Status Scale (EDSS) score less │      99 │
│ than equals to (\<=) 5.0                           │ than equals to (<=) 5.0                            │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                              │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Active malignancy or history of malignancy │      35 │
╘═══════════════════════════════════╧════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.28571428571429
OverAll Ratio: 97.14285714285714
